Last edition
News about "FDA-Approved Therapy"
Thryv Therapeutics Initiates Wave II Phase II/III Trial for Long QT Syndrome Type 2
Thryv Therapeutics has launched the Wave II Phase II/III trial to evaluate THRV-1268, an oral SGK1 inhibitor, as a potential disease-modifying therapy for adults with Long QT Syndrome Type 2.
FDA-approved Therapy | 14/01/2026 | By News Bureau
Citius Oncology Launches Lymphir, a Novel FDA-Approved Therapy for Relapsed or Refractory CTCL
According to Leonard Mazur, chairman and CEO of Citius Oncology and Citius Pharmaceuticals, the launch of Lymphir marks a major milestone for the company. He highlighted its median time to response of 1.4 months, noting that the therapy may provide rapid relief from the severe and debilitating itching associated with CTCL.
FDA-Approved Therapy | 04/12/2025 | By Darshana | 105
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy